Vanguard Group Inc. Has $49.63 Million Stake in Biohaven Ltd. $BHVN

Vanguard Group Inc. increased its holdings in Biohaven Ltd. (NYSE:BHVN) by 52.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,395,946 shares of the company’s stock after buying an additional 1,520,756 shares during the period. Vanguard Group Inc. owned 4.15% of Biohaven worth $49,630,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. PNC Financial Services Group Inc. raised its position in shares of Biohaven by 113.7% in the third quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock valued at $36,000 after buying an additional 1,268 shares in the last quarter. Focus Partners Wealth acquired a new stake in shares of Biohaven in the third quarter valued at approximately $87,000. Tower Research Capital LLC TRC raised its position in Biohaven by 198.6% during the second quarter. Tower Research Capital LLC TRC now owns 8,031 shares of the company’s stock valued at $113,000 after purchasing an additional 5,341 shares in the last quarter. Quantbot Technologies LP raised its position in Biohaven by 1,097.8% during the second quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock valued at $125,000 after purchasing an additional 8,102 shares in the last quarter. Finally, Osaic Holdings Inc. raised its position in Biohaven by 150.5% during the second quarter. Osaic Holdings Inc. now owns 9,791 shares of the company’s stock valued at $147,000 after purchasing an additional 5,883 shares in the last quarter. 88.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have commented on BHVN shares. TD Cowen boosted their price objective on shares of Biohaven from $15.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Royal Bank Of Canada lowered their price objective on shares of Biohaven from $23.00 to $22.00 and set an “outperform” rating for the company in a research report on Tuesday, May 5th. Raymond James Financial restated a “strong-buy” rating on shares of Biohaven in a research report on Monday, March 9th. Wall Street Zen downgraded shares of Biohaven from a “sell” rating to a “strong sell” rating in a research report on Sunday, April 26th. Finally, HC Wainwright lowered their price objective on shares of Biohaven from $11.00 to $10.00 and set a “neutral” rating for the company in a research report on Wednesday, March 4th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $22.27.

Biohaven Stock Performance

NYSE BHVN opened at $8.74 on Friday. Biohaven Ltd. has a fifty-two week low of $7.48 and a fifty-two week high of $18.57. The stock has a market cap of $1.32 billion, a PE ratio of -1.54 and a beta of 1.32. The company has a debt-to-equity ratio of 1.87, a quick ratio of 7.41 and a current ratio of 7.41. The firm’s fifty day moving average price is $9.57 and its two-hundred day moving average price is $10.65.

Biohaven (NYSE:BHVN) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). On average, equities analysts expect that Biohaven Ltd. will post -2.97 EPS for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.